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Abstract
Commutability is a property of a reference material (RM) that relates to the closeness of 
agreement between results for an RM and results for clinical samples (CSs) when measured by ≥ 2 
measurement procedures (MPs). Commutability of RMs used in a calibration traceability scheme 
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is an essential property for them to be fit for purpose. Similarly, commutability of trueness 
controls or external quality assessment samples is essential when those materials are used to assess 
trueness of results for CSs. This report is part 1 of a 3-part series describing how to assess 
commutability of RMs. Part 1 defines commutability and addresses critical components of the 
experimental design for commutability assessment, including selection of individual CSs, use of 
pooled CSs, qualification of MPs for inclusion, establishing criteria for the determination that an 
RM is commutable, generalization of commutability conclusions to future measurements made 
with the MPs included in the assessment, and information regarding commutability to be included 
in the certificate for an RM. Parts 2 and 3 in the series present 2 different statistical approaches to 
commutability assessment that use fixed criteria related to the medical decisions that will be made 
using the laboratory test results.
Background
A challenge in laboratory medicine is that lack of agreement between results among 
different measurement procedures (MPs)16 means that results may not be suitable for 
medical decisions based on those laboratory results. One of the contributors to lack of 
agreement is using noncommutable reference materials (RMs) as calibrators in the 
calibration hierarchy for clinical laboratory MPs. In this series of articles, we consider how 
to decide whether an RM has suitable commutability to be used as a common calibrator in 
the calibration hierarchy of MPs, as a trueness control material provided by an MP 
manufacturer to verify calibration, or as an external quality assessment (EQA) or proficiency 
testing sample. In this part, we describe the common requirements for the experimental 
design. In parts 2 and 3, we present 2 different statistical approaches for assessment of 
commutability. Part 2 is suitable for use when an RM is intended for use as a calibrator, a 
trueness control, or an EQA material (1). Part 3 is suitable for use only when the RM is 
intended for use as a calibrator (2).
This series of articles recognizes the terms MP and measuring system (MS) as described in 
the International Vocabulary of Metrology (VIM) (3). An MP refers to a written 
specification for how a measurement is performed, including a technical description of 
reagents, calibrators, equipment, instrument, and other details necessary to create and 
operate an MS that implements those specifications. An MS is a physical in-vitro diagnostic 
(IVD) medical device manufactured according to the MP specifications and used to make 
measurements on clinical samples (CSs) to produce results (quantity values) that are used in 
research and to make medical decisions for patient care. For example, hundreds of the same 
MS can be manufactured as an implementation of a single MP; the MSs are used by 
different clinical laboratories to produce results for CSs. Another example of an MS is one 
developed by a clinical laboratory that is an implementation of an MP developed by that 
laboratory for its own use (frequently called a laboratory-developed test). Results for an RM 
and for CSs measured using different MSs are used to assess commutability of an RM. The 
conclusion regarding commutability is assumed to be applicable to all other MSs that are 
16Nonstandard abbreviations:MP, measurement procedure; RM, reference material; EQA, external quality assessment; MS, measuring 
system; VIM, International Vocabulary of Metrology; IVD, in-vitro diagnostic; CS, clinical sample.
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implementations of the same MP. For simplicity, in this series of reports we use the term MP 
when referring to either an MP or results from a specific MS that is an IVD medical device 
representative of the MP.
Differences in results among MPs may be because of the following sources of error: (a) 
variation within runs, including trends, caused by variation in performance conditions; (b) 
variation between runs caused by random error in establishing the calibration response 
function and interaction between performance conditions and calibrator properties; (c) errors 
in the assigned values of calibrators; (d) an unsuitable calibration model, for example, a 
linear model when the relationship between response and concentration (i.e., amount of 
substance present or other quantity value) is nonlinear; (e) difference in response to 
influence quantities between the calibrators and the CSs intended to be measured (this 
difference causes a different relationship between signal and concentration for calibrators 
than for CSs that is a systematic error referred to as noncommutability of the calibrator; see 
later definition); (f) differences in response to influence quantities that differ among CSs, 
referred to as sample-specific effects; and (g) differences in selectivity for the measurand.
When we compare results for CSs measured in 1 run with ≥ 2 MPs, as in a commutability 
assessment, we can only estimate the combined effect of the error sources b through e. The 
error sources c through e contribute to systematic differences in results for CSs between 
MPs. The systematic difference (bias) between 2 MPs can be expressed by a constant or a 
function of the concentration.
The effects of error sources e, f, and g above depend on the selectivity of the MPs for the 
measurand. Error source e contributes to the noncommutability of an RM intended for use as 
a common calibrator for a number of MPs and is the subject of this report. If an RM is 
commutable with CSs in the measurement responses of MPs, the RM can be used in the 
calibration traceability schemes for the MPs to reduce the systematic differences among the 
results for CSs to produce equivalent results for CSs, within stated limits, irrespective of the 
MP used.
The sample-specific effects in error source f above may be a confounding issue in assessing 
commutability of an RM. If we consider a specific CS, the sample-specific error can be 
considered as systematic (it cannot be reduced by repeated measurements), but in a 
population of CSs, the sample-specific errors of individual CSs appear as random variability 
to which we can assign an SD. Consequently, the magnitude of sample-specific effects can 
influence a commutability assessment and can be estimated in the experimental design in 
part 2 of this series (1).
Definition of Commutability
The VIM defines commutability as a property of an RM, demonstrated by the closeness of 
agreement between the relation among the measurement results for a stated quantity in this 
material, obtained according to 2 given MPs, and the relation obtained among the 
measurement results for other specified materials (3). For medical laboratories, other 
specified materials are the CSs intended to be measured, and the quantity is usually referred 
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to as the measurand. The CSs may come from healthy volunteers, patients visiting a clinic, 
or patients with disease. The definition of commutability of an RM concerns 2 MPs. When 
applied to a calibration traceability scheme as described in ISO 17511, IVD medical devices
—Measurement of quantities in biological samples—Metrological traceability of values 
assigned to calibrators and control materials, the definition is applicable for each 
combination of 2 MPs used in the traceability scheme. However, when the definition is 
applied to an RM intended for use by several different MPs for a measurand, the 
experimental design for commutability assessment should include all MPs for which an RM 
is intended to be used.
Commutability can be stated as a property of an RM that indicates how well an RM mimics 
the characteristics of typical CSs in an MP for a stated measurand. Commutability is 
important for RMs used in a calibration hierarchy to ensure that the results for CSs measured 
in clinical laboratories will be equivalent irrespective of the MP used. Equivalent means 
within limits determined by the medical requirements for use of a laboratory test result in a 
patient care decision.
The VIM definition of measurand (the quantity intended to be measured) has limitations 
when applied to assessment of commutability. The chemical species being measured is the 
important consideration when selecting samples or qualifying MPs for inclusion in assessing 
commutability of an RM. In some cases, more than 1 chemical species may be measured 
either intentionally or because of poor selectivity of an MP. EQA data from commutable 
samples may identify MPs that do not measure the same quantity. Alternatively, the 
subgroups in an EQA scheme may represent an inadequately defined measurand in the EQA 
material. In such situations, the quantity to be measured may need to be more clearly 
defined.
Assessment of Commutability
Assessment of commutability requires the following steps: (a) obtain RM(s) to be evaluated; 
(b) obtain representative CSs; (c) measure the RM(s) and CSs using the MPs included in the 
commutability assessment; and (d) apply a procedure to evaluate the commutability of the 
results for RM(s) in relation to the results for the CSs. Currently available procedures to 
assess commutability use criteria based only on the statistical distribution of differences in 
results for CSs between 2 MPs; thus, the criteria can be different for different pairs of MPs 
with different precision performance (4, 5). Criteria for commutability assessment should be 
the same for all MPs in an assessment and should be based on the influence of differences 
between RM and CSs on medical decisions made using the laboratory test results. The 
statistical approaches in parts 2 and 3 in this series present commutability assessment 
procedures that can use criteria based on medically relevant differences in results between an 
RM and CSs (1, 2).
An example of commutability assessment based on the approach in part 2 of this series is 
shown in Fig. 1. The bias between 2 pairs of MPs (x and y; x and z) is shown for a panel of 
CSs and for 5 candidate RMs. The relative bias is constant over the concentration interval 
for the CSs; consequently, the average bias of the CSs is suitable for assessment at each of 
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the RM concentrations examined. The error bars for each RM indicate the uncertainty of the 
difference in bias between that RM and the average bias of the CSs. The uncertainty consists 
of 2 components: the uncertainty of the estimate of bias for the CSs and the uncertainty of 
the estimate of bias for each RM.
The blue dashed lines in Fig. 1 indicate the predetermined maximum allowable bias for the 
commutability of the RM to be considered sufficient to fulfill medical performance 
requirements for its intended use. The criterion is the same for all pairs of MPs examined. 
An RM is commutable when the bias of the RM including the error bars is completely 
within the blue dashed lines. In Fig. 1A, RM1, RM3, and RM5 are commutable with the CSs 
because their bias, including the error bars, is within the blue dashed lines. RM2 and RM4 
are not commutable with the CSs because the error bars are completely outside the blue 
dashed lines. In Fig. 1B, the criterion is the same because it is based on medical use 
requirements. However, there is more scatter in the CS results, suggesting MP z has a larger 
random error component. The increased scatter is reflected in larger error bars that now 
make the commutability of RM1, RM2, and RM5 indeterminate because the error bars are 
outside of the blue lines. The assessment of commutability illustrated in the Fig. 1 example 
reflects data from CSs and MPs that qualified to be included in the assessment as described 
in sections that follow.
Individual CSs for Assessment of Commutability
Individual CSs are the matrix that a clinical laboratory MP is designed to measure. 
Consequently, CSs represent ideal samples to establish the relationship between different 
MPs. A commutability assessment is intended to qualify an RM as suitable for use as a 
calibrator, trueness control material, or EQA sample. A commutability assessment is not 
intended to evaluate the selectivity of MPs for the measurand. In most cases, an RM is 
intended to simulate the types of CSs commonly encountered when measuring a given 
measurand.
CSs should be selected with consideration of MP selectivity limitations. The influence of 
interfering substances in an individual CS can make it unsuitable for use in a commutability 
assessment. CSs should be excluded that are known to contain interfering substances or 
unusual molecular forms, such as found in less common pathologic conditions, when these 
affect all or most of the MPs in a study. Sourcing more CSs than the minimum needed for 
statistical assessment is recommended to ensure that enough usable data will be available to 
meet the statistical requirements for a study. The presence of an interfering substance or 
unusual molecular form in a CS may not be known until identified as an outlier result in data 
analysis.
Note that qualification of MPs to be included in a study (see subsequent section of this 
report) should be done before setting requirements for exclusion of CSs so that MPs with 
inadequate selectivity will not compromise the usefulness of the evaluation of commutability 
of an RM. In some EQA applications, an RM may contain an uncommon molecular form for 
the purpose of challenging the selectivity of MPs. Such special cases are outside the scope of 
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the usual purpose for a commutability assessment and are not addressed in these 
recommendations.
The interval of concentrations (quantity values) of the measurand in CSs must include that 
of the RM(s) but does not need to cover the entire measuring interval for the MPs included 
in the commutability assessment. The number of CSs needed will vary with the experimental 
design and the performance characteristics of the MPs in the commutability assessment. For 
measurands that have large differences in measuring interval for different clinical uses, for 
example, C-reactive protein, commutability assessment may be restricted to 1 of the 
intended use intervals or may require separate experiments for each interval. The 
concentrations for the RM(s) and CSs must be within the measuring intervals of the MPs 
included in an assessment.
CSs must be collected and aliquots prepared, stored, and distributed such that no alteration 
of the measurand or matrix occurs. For practical reasons, it may be necessary to store 
samples before a commutability assessment. Use of preservatives, freezing or other storage 
conditions, pooling, or any modification to an individual CS may affect commutability and 
should be evaluated for suitability in a preliminary experiment. Some measurands in CSs are 
not stable for prolonged times under defined storage conditions. Such situations need to be 
considered in the experimental design for a commutability assessment. Aliquots of 
individual CSs used for a commutability assessment should be retained when possible to use 
for commutability assessment of new MPs or MPs that were excluded because they required 
improvement in performance.
Pooled CSs for Assessment of Commutability
Although individual CSs are preferred for a commutability assessment, sufficient volumes of 
individual CSs cannot always be obtained to enable aliquoting for distribution and 
measurement by all MPs in a commutability assessment. In this case, using pooled CSs 
instead of single donations is a practical solution that may reduce the cost and complexity of 
a commutability assessment. Pooling dilutes the influence of a substance present in an 
individual donor sample. Pools prepared from many single donations are more likely to 
reduce the influence of a few individual donors with sample-specific effects. Consequently, 
pooled samples cannot be used to assess sample-specific effects in the statistical analysis.
When preparing pools, the individual donors should meet the same requirements as 
described for individual CSs used alone. A preliminary experiment should be performed to 
demonstrate that pooled CSs and their storage conditions are suitable surrogates for 
individual CSs. Pooled CSs may have matrix alterations that cause them to be 
noncommutable with individual CSs. Consequently, pooled CSs should be validated to be 
commutable with individual CSs before being used for commutability assessment of RMs. 
Demonstrating that some pools are commutable does not guarantee that other pools prepared 
in the same manner will also be commutable, but it is a reasonable assumption. When 
sufficient volume of donor samples is available, Clinical and Laboratory Standards Institute 
document C37 (6) includes a validation scheme to demonstrate commutability of a pool 
based on recovery of a value expected from the proportion of each donor sample used to 
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prepare the pool. When pooled CSs are used for commutability assessment, their preparation 
and qualification must be fully documented.
RM(s) to Include in an Assessment of Commutability
Candidate RM(s) intended for use as calibrators in a calibration hierarchy (7), as trueness 
control materials, or as EQA samples are typically produced by an organization that assesses 
their commutability as part of the qualification for intended use. When RMs are intended to 
be used after dilution to obtain quantities within the measuring interval of the MPs, the 
diluted RMs must be evaluated for commutability. The manufacturer of an RM that is 
intended to be diluted before use should provide instructions for making the dilutions that 
address compatible or incompatible diluents and other known influences that could affect the 
performance of the diluted RM.
RMs intended to be used as common calibrators by different MPs must be commutable. 
However, product calibrators (end-user calibrators) that are provided by an IVD 
manufacturer intended for use only with a specifically identified MP are not required to be 
commutable. When necessary, the value assignment of such product calibrators can 
compensate for a known and constant noncommutability bias such that patient results from 
that specific MP are traceable to higher order references. Such calibrators are validated and 
intended for use only with MPs specifically identified by the IVD manufacturer and are not 
intended to be used with any other MP.
Qualification of MPs for Inclusion in a Commutability Assessment
Cooperation with manufacturers of MPs is important during RM development to anticipate 
and minimize possible constraints related to an assessment of commutability. An MP 
manufacturer may be an IVD medical device manufacturer or a laboratory that develops its 
own MP. It is desirable to include as many different MPs and analytical measurement 
principles as possible in a commutability assessment. However, it may not be possible to 
include all MPs in a commutability assessment. Including the most representative group of 
MPs will improve the likelihood of an RM being suitable for use with other MPs not 
included in the initial assessment or with a new MP that may enter the market. 
Considerations for inclusion include market share for commercially available MPs and types 
of analytical measurement principles. For laboratory-developed tests, inclusion can be based 
on methods used on a large scale or offered as a service to other laboratories. The 
manufacturer of an MP is responsible to ensure that an RM is commutable and suitable for 
use in a calibration hierarchy.
MPs to be included in a commutability assessment must have acceptable performance 
characteristics as described below. Improvement of some MPs may be a required precursor 
to inclusion in a commutability assessment. An MP manufacturer may require substantial 
time to improve an MP and may have to make provision for a follow-up commutability 
assessment of an RM when MP improvements have been addressed.
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MP precision
MPs must have adequate precision because inadequate precision can inappropriately 
influence assessment of commutability. For example, a value for a measurand from an MP 
with inadequate precision will have larger uncertainty that could compromise assessment of 
commutability for that MP. There are no fixed guidelines for adequate precision. 
Considerations for acceptable precision will be determined by the experimental design that 
in turn will be influenced by the criteria for acceptable commutability, availability of CSs 
with sufficient volume for replication, and cost for distributing materials and making 
measurements. The desired closeness of agreement between RM and CSs that needs to be 
identified in the commutability assessment should be determined, and the required precision 
of MPs can be estimated based on statistical power analysis. The replication of 
measurements is an experimental design detail that can be adjusted to reduce random error.
MP selectivity
MPs to be included in a commutability assessment must have adequate selectivity for the 
measurand. MPs with inadequate selectivity could inappropriately disqualify an RM that 
may be suitable for use with many MPs being used by clinical laboratories. Inadequate 
selectivity is identified as bias in an individual CS, called a sample-specific effect, that is 
greater than the typical bias for other CSs and is caused by the influence of substances other 
than the measurand on the measurement signal, or by differences in response to the 
measurand by different MPs. A sample-specific effect is a systematic error (bias) for an 
individual CS that can be considered a random component of bias within a group of CSs that 
cannot be reduced by replication or calibration.
The selectivity of MPs for which the RM will be used must be considered when determining 
whether adequate commutability can be demonstrated. It may not be possible to demonstrate 
adequate commutability of an RM with an MP that has excessive sample-specific effects. 
The MP manufacturer will need to improve the selectivity for the measurand to enable the 
RM to be suitable for use with that MP. Ideally, inadequate selectivity will be identified in a 
qualification assessment or a preliminary experiment. However, the nonselectivity may not 
be recognized until the commutability assessment is performed, in which case results for 
that MP should be excluded from a commutability assessment of an RM for other MPs for 
which the RM may be suitable for use.
Selectivity of an MP can be concentration-dependent, for example, if different molecular 
forms of an analyte are produced in disease conditions. An example of a selectivity 
limitation is the presence of molecular forms that may not be measured in a consistent ratio 
by different MPs. MPs that recover the same ratio can be included; others may need to be 
excluded until they can be modified to recover the same ratio. An expert group may need to 
determine which molecular forms and ratios are appropriate for the medical use of the 
laboratory test.
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Criteria to Determine That an RM is Commutable
The intended use of an RM will influence the choice of a criterion for commutability. The 
criterion for commutability of an RM relates to the allowable bias for an individual CS result 
(8). Several approaches to determine the allowable bias for a CS result have been described 
that consider the risk of harm to a patient from medical decisions based on uncertainty in a 
measurand result for a CS (9). The criterion for commutability for an RM intended for use as 
a calibrator in a calibration hierarchy for an MP should be a fraction of the uncertainty 
required at the relevant position in the hierarchy to achieve the allowable bias in a CS result.
EQA or trueness control materials are usually intended to verify (not establish) that an 
individual result is within an acceptable measurement error. The criterion should consider 
that EQA and trueness control materials are usually measured in singlicate or a few replicate 
measurements. Consequently, both bias and imprecision can influence a measured value. 
The criterion for commutability should be a fraction of the bias component of the acceptance 
limits for evaluating an EQA or trueness control result.
Closeness of agreement is a relative term, and some RM results may have closer agreement 
with results for CSs and, thus, better commutability for some MPs than for others. A 
criterion based on the intended medical use of laboratory test results is preferred but needs to 
be established with consideration of MP performance capability. The criterion for a 
conclusion that an RM is commutable based on medical requirements should be established 
at the beginning of a commutability assessment. If no available RM can meet the criterion, 
the criterion may be reconsidered to permit production of an RM that when used in a 
calibration hierarchy substantially improves agreement of results for CSs among different 
MPs such that medical decisions are improved and the risk of harm to a patient is reduced.
Criteria related to MP performance characteristics
Criteria based on statistical distribution of CS results between MPs are less desirable and not 
recommended because they can produce different criteria for different combinations of MPs 
for the same measurand. Criteria based on statistical distribution of CS results may be 
unreasonably small or large compared with the intended medical use of laboratory test 
results. Criteria based on statistical limits expect some fraction of RM–MP combinations to 
fail to meet the criteria that could cause an erroneous conclusion regarding the RM being fit 
for purpose. However, a criterion related to achievable performance of available MPs may be 
acceptable if the same criterion is used for all MPs in a commutability assessment.
In some cases, practical limitations in study design (e.g., limited number of replicates or 
limited number of CSs) and/or the performance capability of all or many MPs (e.g., poor 
precision or high susceptibility to sample-specific effects) could produce large uncertainties 
that could cause high rates of inconclusive commutability decisions and limit the ability to 
make a decision about suitability of an RM (10, 11). In such situations, using a less stringent 
acceptance criterion accounting for the study design and performance capability of MPs can 
be considered. In this situation, the claimed use of the RM should be reconsidered 
accordingly.
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Criteria for a set of calibrators
Criteria for a set of calibrators intended to be used together to cover a measuring interval 
need to be considered as a group. When different concentrations of RMs are prepared 
independently, each RM should be independently evaluated for commutability. If RMs are 
prepared by a process such as admixing 2 concentrations or another approach that provides 
common characteristics between the materials, then each RM concentration may have the 
same or similar relationship (i.e., bias) when compared with the results from CSs. In this 
case, the commutability of the RM may be considered as a set. If the variability of results 
[i.e., SD, CV, SD(log)] for an MP is different at different measurand values (concentrations), 
then the data may need to be partitioned accordingly (readers may refer to Clinical and 
Laboratory Standards Institute document EP09 for procedural details on partitioning) (12). 
Criteria based on medical requirements may be different at different concentrations (quantity 
values).
Fraction of MPs for which a RM is commutable
A number of MPs will be included in the assessment of commutability of an RM. Ideally, an 
RM will be commutable for all MPs that it might be used with. However, this goal is not 
always achievable, and in many cases there will be some MPs for which the RM is not 
commutable. An RM intended for use as a common calibrator should be commutable for a 
sufficient fraction of MPs that an improvement in medical decisions will occur. Similarly, 
when an RM is intended to be used as a trueness control or an EQA sample, its 
commutability should be suitable to obtain useful information on trueness and performance 
for most of the laboratories and MPs that use the RM.
There are no simple recommendations for the fraction of available MPs for which an RM 
must be commutable that would qualify an RM as being fit for purpose. Considerations 
include the market share for MPs and consequently the number of tested individuals who 
may be affected. Note that market share can be different in different regions of the world. 
Another consideration is the overall health improvement that would follow from use of an 
RM in a calibration hierarchy even if it failed the preestablished criteria for commutability 
for some fraction of MPs in use. In such a case, the criteria could be reconsidered based on 
the impact on medical decisions of using a less stringent criteria.
Generalization of Commutability of an RM to Future Measurements
The conclusions from a commutability assessment are strictly applicable to only the MPs 
and measurement conditions (reagent lot and other parameters) used in the experiment. It 
may be possible to use several reagent lots, calibration events, and IVD medical devices of 
the same MPs in a commutability experiment, but in many cases such duplication is not 
realistically achievable. The experiment typically assumes that the MPs and measurement 
conditions are representative of those that will be encountered in medical laboratories and 
that the conclusions regarding commutability of an RM will be maintained when used with 
other IVD medical devices of the same MPs, as well as for other reagent lots and measuring 
conditions in the future. The assumption is accepted as reasonable in laboratory medicine, 
but users should keep in mind that changes in reagents or measuring conditions can occur 
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that could make conclusions from a commutability assessment no longer applicable. The 
more substantial a change, such as a change in reagent formulation, the greater is the risk 
that commutability conclusions may no longer be valid. In such cases, a commutability 
assessment should be repeated to ensure that an RM remains suitable for its intended use.
Information on Commutability to be Provided to the User of an RM
Table 1 includes the information regarding commutability assessment that should be 
documented for a certified RM, trueness control material, or commutable EQA material. The 
certificate of analysis should include a summary of the Table 1 information with details at 
the discretion of the RM manufacturer. All the information must be provided on request to 
users of an RM. It is recommended that the results of a commutability assessment for an RM 
intended to be used in a calibration hierarchy or as a trueness control be published in a peer-
reviewed journal.
Conclusion
This report provides recommendations for critical components of the experimental design 
for commutability assessment, including selection of individual CSs, use of pooled CSs, 
qualification of MPs for inclusion in the assessment, establishing a criterion for the 
determination that an RM is commutable that is the same for all MPs and is related to how a 
test result is used in medical decisions, generalization of commutability conclusions to 
future measurements made with the MPs included in the assessment, and information 
regarding commutability to be made available to a user of the RM and included in the 
certificate for an RM.
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Fig. 1. The bias for logarithmic transformation of concentration [ln(concentration)] between 2 
measuring systems is shown for a panel of CSs (black diamonds) and for 5 candidate RMs (red 
squares) vs the mean concentration measured with each MP
The error bars for each RM indicate the uncertainty of the difference in bias between each 
RM and the average bias for the CSs. The bias values for in-transformed results can be 
multiplied by 100 to give an approximate percent bias. The black solid line is the mean bias 
(18%) for all the CSs. The blue dashed lines indicate the maximum allowable 
commutability-related bias for the RM to be considered commutable with the CSs. (A) 
shows results for 2 MPs (x and y) for which the random errors of the MPs and the sample-
specific influences are reasonably small. (B) shows results for 2 MPs (x and z) with more 
scatter for the CS results, suggesting that MP z has poorer precision and/or larger sample-
specific influences in relation to MP x.
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Table 1
Information to be included in the documentation of an RM that is commutable for a stated number of MPs.
Selection criteria for individuals from whom CSs were obtained for the commutability assessment
Number of CSs used in the commutability assessment and their collection, processing, storage, and distribution conditions
Description of the experimental design used to assess commutability; state the reference MP if included in the experimental design
Criteria used to conclude that an RM was commutable with clinical samples
Summary of the results of the commutability assessment in sufficient detail that the conclusions can be verified; complete experimental results 
and data analysis must be available to a user on request
MPs for which commutability was demonstrated, including the specific models of instruments and the part numbers and lot numbers of 
reagents, calibrators, and calibration confirmation materials
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